Document:

Exhibit 10.10

 

CONFIDENTIAL

 

EMPLOYMENT AGREEMENT

 

This agreement is made on the 7 day of December, 2011 between Iradimed Corporation, an Oklahoma corporation, having offices at 7457 Aloma Avenue, Winter Park, Florida (“Iradimed” or “Company’’), and Brent Johnson (“Executive”).

 

WITNESSETH:

 

WHEREAS, Iradimed desires to employ Executive upon the terms and conditions hereinafter stated, and;

 

WHEREAS, Executive wishes to be employed by Iradimed on the terms and conditions contained in this Agreement.

 

NOW, THEREFORE, in consideration of the facts, mutual promises and covenants contained herein and intending to be legally bound thereby, Iradimed and Executive agree as follows:

 

1.                                      Employment.  Iradimed shall employ Executive, and Executive hereby accepts employment by Iradimed, for the period and upon the terms and conditions contained in this Agreement, beginning the 2nd day of January 2012.

 

2.                                      Title and Duties.  Executive shall serve Iradimed as Executive Vice President of Worldwide Sales and Marketing.  Executive will report to the President and shall have such authority and responsibilities as delegated or assigned from time to time as delegated or assigned by the President.  Executive shall primarily be responsible for meeting revenue and sales cost objectives (Revenue Plan), an initial such Revenue Plan is hereby attached for reference, and for developing and maintaining sales personnel meeting such Plan goals.

 

3.                                      Term.  This Agreement shall commence as of the date hereof and shall continue until terminated in accordance with Sections 7 and 8 below.

 

4.                                      Policies.  Except as provided herein, Executive shall be covered by and agrees to comply with all Iradimed policies on the same terms as are applicable to other full-time executives.

 

5.                                      Extent of Services.  Executive shall devote his entire business and professional time and attention to the business of Iradimed.  Executive shall assume and perform his duties faithfully and with due diligence.  Executive shall not engage in any other occupation or business activity for the duration of this Agreement without the prior written consent of Iradimed, which consent shall be given or withheld at Iradimed’s sole discretion.

 

 

6.                                      Compensation.

 

(a)                                 Base Salary.  The Company shall pay Executive a minimum annual salary of one hundred seventy five thousand dollars ($175,000), or in the event of any portion of a year, a pro rata amount of such annual salary.  Executive’s salary will be payable as earned in accordance with the Company’s customary payroll practice.  Executive shall also be entitled to a merit increase based on his base salary and subsequent to performance review, on his anniversary date beginning on January 3, 2013 and each year thereafter while Executive is employed by the Company.

 

(b)                                 Bonuses.  For the fiscal year ending December 31, 2012, Executive will be eligible to receive cash bonus compensation as follows: (a) cash bonus paid quarterly on meeting or exceeding 66% (two thirds) of total sales revenues at a rate payout of $25,000 at the 2012 Revenue Plan (example $25,000 / $5,000,000 = .005% x quarterly sales revenue); (b) $25,000 end of year bonus payable on achievement of 100% of the 2012 Revenue Plan; (c) end of year overachievement of plan bonus payable as $1,000 for each percentage that 2012 actual revenues exceed 2012 revenue plan.  For 2013 and beyond the bonus plan will be commensurate on the growth and ongoing success of the Company.

 

(c)                                  Equity Compensation.  The Company shall provide Executive with a stock option award that will be subject to the terms and conditions of the Iradimed Stock Option Agreement executed by Executive and Company.  The stock option award will be granted based on the total number of shares outstanding at the time of the award to include preferred stock, common stock and granted options (less 100,000 currently un-exercised options granted to sales personnel) and be awarded on the following schedule: (a) 5% of total shares outstanding awarded on commencement of employment at a company valuation of $8,000,000; (b) 3% of total shares outstanding awarded on November 1, 2012 at a company valuation of $8,000,000; (c) 2% of total shares outstanding awarded on December 31, 2013 at the company’s current valuation at the time of the grant.

 

(d)                                 Benefits.  Executive will be eligible to participate in Iradimed employee benefit plans that apply to all executive employees generally, including without limitation, deferred compensation, health and dental insurance programs, 401 (k) plan, twenty (20) days of paid personal leave, car allowance of not less than $600.00 per month plus fuel expenses, life insurance and similar plans and programs in accordance with the rules established for individual participation in any such plan.

 

7.                                      Termination By Iradimed.

 

(a)                                 Termination For Cause.  Iradimed may terminate Executive’s employment hereunder for “Cause” upon: (a) any material breach of this Agreement; (b) any gross negligence or willful misconduct by Executive in the performance of his duties as an Iradimed employee; (c) Executive’s commission of a felony under the laws of the United States or any state thereof; (d) Executive’s commission or participation in any act of fraud, embezzlement or dishonesty; (e) Executive’s willful breach of an Iradimed policy.  Executive shall not be terminated under subparagraphs (a) or (e) herein, unless he has received written notice of such breach from the Company’s President, has had an opportunity to respond to the notice, and has failed substantially to cure such breach within thirty (30) calendar days of such notice.

 

2

 

(b)                                 Termination Without Cause.  In the event Iradimed terminates Executive’s employment hereunder for any reason other than Cause, such termination shall be deemed “Without Cause.”

 

8.                                      Termination By Executive.

 

(a)                                 Termination for Good Reason.  Executive may terminate his employment hereunder by tendering his resignation to Iradimed.  Unless otherwise consented to in writing by Executive, a resignation by Executive shall be for “Good Reason,” where such resignation is tendered within sixty (60) days following: (a) a reduction in Executive’s minimum salary; (b) a significant diminution of Executive’s authority; or (c) the relocation of Executive’s place of employment outside of a fifty (50) mile radius from its present location.  For purposes of this Agreement, significant diminution of authority is recognized as notification to Executive of a change in status, position, responsibilities, or any adverse change to compensation which is not broadly applied to management in the Company, which, in Executive’s reasonable judgment, represents a material adverse change from his status, position or responsibility.  Prior to accepting Executive’s resignation for any of the reasons set forth in this paragraph, the Company shall have an opportunity to rectify the matter that gave rise to Executive’s resignation. If the matter is not rectified within fifteen (15) days, Executive’s resignation shall be deemed accepted by the Company.

 

(b)                                 Resignation in connection with a Control Transaction.  A resignation of Executive shall also be for “Good Reason” where such resignation is tendered within sixty (60) days following any of the events listed below and such event occurs within twelve (12) months following a Control Transaction as defined in Section 8(c):

 

(i)                                     an assignment to Executive of any duties inconsistent with, or a significant change in the nature or scope of Executive’s authority or duties from, those held by Executive immediately prior to the Control Transaction;

 

(ii)                                  a reduction in Executive’s annual salary or bonus program in effect immediately prior to the Control Transaction;

 

(iii)                               the relocation of Executive’s place of employment outside of a fifty (50) mile radius from its present location;

 

(iv)                              the failure to provide Executive with a number of paid personal leave days at least equal to the number of paid personal leave days to which he was entitled in the last full calendar year prior to the Control Transaction;

 

3

 

(v)                                 the failure to provide Executive with substantially the same fringe benefits that were provided to Executive immediately prior to the Control Transaction, or with a package of fringe benefits that, though one or more of such benefits may vary from those in effect immediately prior to the Control Transaction, is, in Executive’s opinion, substantially at least as beneficial to Executive in all material respects to such fringe benefits taken as a whole;

 

(vi)                              the failure to obtain the express written assumption of and agreement to perform the obligations in this Agreement by any successor.

 

(c)                                  Control Transaction.  In this Agreement, a “Control Transaction” means a change in control of the Company defined as a transfer of ownership of more than 50% of the outstanding shares of the Company’s stock.

 

9.                                      Disability.  If, during the term of this Agreement, Executive becomes disabled such that he is not able to effectively discharge his duties under this Agreement, with or without reasonable accommodation, for a period of six (6) continuous months, Iradimed’s obligations under this Agreement shall cease, except that Executive may participate in any Iradimed-provided group disability benefits in accordance with the terms of those plans.

 

10.                               Consequences of Termination.

 

(a)                                 Compensation.

 

(i)                                     In the event that Iradimed terminates Executive’s employment hereunder Without Cause or Executive resigns from Iradimed with Good Reason, then Iradimed shall pay to Executive the full amount of any earned but unpaid Base Salary through the date of termination, his accrued and unused vacation leave as of the last day worked, his approved business expenses, the full amount of any unpaid cash bonus for any fiscal years prior to the date of termination and an amount equal to twelve (12) months Base Salary.  Such payment shall be made within fifteen (15) days of the effective date of resignation or termination.

 

(ii)                                  In the event that Iradimed terminates Executive’s employment hereunder for Cause or Executive resigns without Good Reason, Iradimed shall pay Executive his earned and unpaid Base Salary and his accrued and unused vacation leave as of the last day worked, and approved business expenses and Iradimed shall have no obligation to make any further payments to or to provide any further benefits hereunder to Executive.  Such payment shall be made within fifteen (15) days of the effective date of resignation or termination.

 

11.                               Noncompetition/Nonsolicitation/Confidentiality.  Executive agrees to execute a Covenant Not to Compete and Confidentiality Agreement simultaneously with the execution of this Agreement.

 

4

 

12.                               Ownership of Developments.  All information, data, ideas, customer lists or other material which Executive develops or conceives during his employment, (1) which are along the lines of business, work or investigations of the Company, or (2) which result from or are suggested by any work performed by Executive on behalf of the Company, shall be the exclusive property of the Company, shall be promptly disclosed to the Company, and Executive will promptly execute and deliver all documents and do all other things necessary and proper to make all such information, data, ideas, customer lists or other material the absolute property of the Company.  Executive agrees to assist the Company in every proper way to obtain for the Company’s benefit copyrights, patents, or other appropriate legal protection for information, data, ideas, customer lists or other material that become the exclusive property of the Company.

 

13.                               Notices.  Any notice required or desired to be given under this Agreement shall be deemed given if in writing and sent by certified mail to the addresses set forth below. Notice shall be deemed given immediately if delivered in person or within three (3) days after mailing by certified mail to the following addresses:

 

	
Brent Johnson
    	
 
    	
Roger Susi, President
    Iradimed Corporation
    7457 Aloma Ave.
    Winter Park, FL 32792
    

 

Any party may alter the address to which communications or copies are to be sent by giving notice of such change of address in conformity with the provisions of this paragraph for the giving of notice.

 

14.                               Assignment.  Executive acknowledges that his services are unique and personal and that he therefore may not assign his rights or delegate his duties under this Agreement.  This Agreement shall inure to the benefit of and be binding on Iradimed, its successors and assigns, including, without limitation, any entity which is or may become affiliated with or related to Iradimed.

 

15.                               Waiver.  Failure to insist upon strict compliance with any term or condition of this Agreement shall not be deemed a waiver of such term or condition.  The waiver of a breach of any term or condition of this Agreement by any party shall not be deemed to constitute the waiver of any other breach of the same or any other term of condition.

 

16.                               Entire Agreement.  This Agreement contains the entire agreement of the parties relating to the subject matter hereof, and the parties hereto have made no agreements, representations, or warranties relating to the subject matter of this Agreement that are not set forth herein.  No modification of this Agreement shall be valid unless made in writing and signed by the parties hereto.  Section headings are for convenience only, and are neither a part of this Agreement nor a limitation of the scope of the particular sections to which they refer.

 

17.                               Governing Law.  This Agreement shall be construed in accordance with the laws of the State of Florida.

 

5

 

18.                               Severability.  The provisions of this Agreement are severable, and if any provision(s) or any part of any provision(s) is held to be illegal, void or invalid under applicable law, such provision(s) may be changed to the extent reasonably necessary to make the provision(s), as so changed, legal, valid and binding, and to reflect the original intentions of the parties as nearly as possible in accordance with applicable law.  This Agreement shall be construed according to its fair meaning and not strictly for or against either party.

 

19.                               Venue and Jurisdiction.  The parties to this Agreement hereby expressly and irrevocably elect as the sole judicial forum for the adjudication of any matters arising under or in connection with this Agreement, and consent and subject themselves to the jurisdiction of the courts of the State of Florida and/or the United States District Court for the Middle District of Florida, Orlando Division.

 

20.                               Execution in Counterparts.  This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original as against any party whose signature appears thereon, and all of which shall together constitute one and the same instrument.  This Agreement shall become binding when one or more counterparts hereof, individually or taken together, shall bear the signatures of all of the parties reflected hereon as signatories.

 

21.                               Attorneys Fees and Costs.  In the event of any litigation, including arbitration, between or among the parties arising out of or relating to this Agreement, the prevailing party shall be entitled to recover from the non-prevailing party all costs incurred and reasonable attorneys’ fees, including attorneys’ fees in all investigations, arbitrations, trials, bankruptcies and appeals.  If any dispute arising out of or relating to this Agreement is submitted to arbitration, the arbitrator or arbitrators shall have the power and authority to, and the parties herby direct that such arbitrator or arbitrators shall, determine entitlement to attorneys fees and costs, and the amount of such attorneys’ fees and costs, to be awarded to the prevailing party.  The parties agree and acknowledge that this provision, while it references arbitration, shall not be read to require the parties to submit to arbitration unless they agree to submit to arbitration in a separate, explicit, provision of this Agreement or in a separate written agreement.

 

6

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and year first above written.

 

	
IRADIMED CORPORATION
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
/s/ Roger Susi
    	
 
    
	
Roger Susi
    	
 
    
	
President
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
EXECUTIVE
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
/s/ Brent Johnson
    	
 
    
	
Brent Johnson
    	
 
    

 

7Exhibit 10.11

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN REDACTED PROVISIONS OF THIS AGREEMENT AND, WHERE APPLICABLE, HAVE BEEN MARKED WITH AN ASTERISK (****) TO DENOTE WHERE OMISSIONS HAVE BEEN MADE.  THE CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

SUPPLY AGREEMENT

 

between

 

Iradimed Corp.

 

and

 

****

 

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN REDACTED PROVISIONS OF THIS AGREEMENT AND, WHERE APPLICABLE, HAVE BEEN MARKED WITH AN ASTERISK (****) TO DENOTE WHERE OMISSIONS HAVE BEEN MADE.  THE CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

THIS Supplier Agreement (“Agreement”) is effective as of January 26, 2014 (“Effective Date”) by and between Iradimed Corp., having its principal place of business at 7457 Aloma Ave. Winter Park, FL 32792 USA (“Iradimed”)

 

And

 

**** having its principal place of business at ****, Japan (“Supplier”)

 

WHEREAS Iradimed is engaged in the development, design engineering, marketing, sales and delivery of various MRI compatible systems and equipment, including MR IV fluid pumping and control devices.

 

WHEREAS Supplier is engaged amongst other things, in the development, design engineering, manufacturing, marketing and sales of Ultra sonic motors and control devises;

 

WHEREAS, subject to Suppliers competitiveness and Iradimeds’ demands, Iradimed desires to purchase from Supplier as its sole suppler, a regular quantity of MR compatible ( non-magnetic) ultra sonic motors and control devices (“Products”) for integration into Iradimeds’ medical systems and Supplier shall sell and deliver to Iradimed such ordered Products, accordingly;

 

NOW, THEREFORE, for and in consideration of the premises and mutual covenants herein contained, parties hereto agree as follows:

 

ARTICLE 1                                                                           TERM

 

1.1                               Unless earlier terminated as provided herein, this Agreement shall have a term of Five (5) years from the effective date of this Agreement.

 

1.2                               Unless terminated earlier in accordance with article 13, this Agreement shall remain in effect until January 25, 2019, and thereafter may be further renewed with mutual written consent of Iradimed and Supplier six (6) months before from expiry date of this Agreement.

 

ARTICLE 2                                                                           SUPPLY OF THE PRODUCTS

 

For purpose of this Agreement, the “Products” mean the specified Ultra Sonic motors as described in Exhibit A and its modified version agreed in writing by the Parties. Subject to the terms and conditions herein contained, Supplier agrees to sell the Products and its control device to Iradimed, Iradimed agrees to purchase the Products and its control device from the Supplier. Supplier further agrees to not sell the Products to any other third party as long as Iradimed perform the yearly minimum purchase obligation as stipulated in Article 3.

 

Also, the Parties confirmed and agreed that the Products have been or will be designed and manufactured by Supplier with Iradimed specification and requirements input, Ultra sonic motors as Exhibit A have been modified and improved from prototype as follows; (i) ****, (ii) ****, (iii) ****, (iv) ****, and (v) ****.

 

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN REDACTED PROVISIONS OF THIS AGREEMENT AND, WHERE APPLICABLE, HAVE BEEN MARKED WITH AN ASTERISK (****) TO DENOTE WHERE OMISSIONS HAVE BEEN MADE.  THE CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

Therefore, the Parties confirmed that the Ultra sonic motors described in Exhibit A may be, from time to time, modified thereafter. Provided, however, that, such modifications shall be valid only by an Agreement in writing signed by the Parties.

 

ARTICLE 3                                                                           YEARLY MINIMUM PURCHASE OBLIGATION

 

Iradimed shall present Supplier with the latest forecast of yearly purchase for each calendar year, at least three (3) months prior to the first date of each contractual year hereinafter set forth.

 

As one of the main conditions prerequisite to the continuation of this Agreement, Iradimed guarantees to purchase the Products from Supplier during the term, in a quantity per year not less than:

 

Each contractual year and yearly minimum purchase of the Products shall be as follows:

 

1st year (2014): five hundred (500) units

 

2nd year (2015): six hundred (600) units

 

3rd (2016) thru 5th (2018): seven hundred (700 units) per year

 

ARTICLE 4                                                                           QUALITY CONTROL SYSTEM

 

Supplier’s quality control system shall comply with and be maintained in accordance with the quality standard; ISO9001/2000 agreed by the parties hereto, or its latest version. Iradimed, or its designates are entitled to carry out, with reasonable prior notice to the Supplier, quality audits at Supplier’s premises according to the filed-work audit standards agreed by the parties.

 

ARTICLE 5                                                                           CHANGE

 

Supplier may not change, substitute or modify the Products without Iradimeds’ prior written Approval.

 

ARTICLE 6                                                                           PAYMENT CONDITION

 

Unless otherwise agreed, Iradimed shall pay in advance by telegraphic transfer in Japanese Yen, all invoices issued by the Supplier, within seven (7) days from the date of invoice, at the selling price to Iradimed by Supplier as set forth the price list of the Products agreed between the parties effective on the order by Iradimed as confirmed by Supplier.

 

ARTICLE 7                                                                           DELIVERY TERM

 

Supplier shall prepare products for delivery within ninety (90) days from purchase order date by Iradimed and seven (7) days prior to the deadline of the delivery, and notify Iradimed accordingly as it become available. Supplier shall send Iradimed the Products within three (3) business days after receipt of Payment, by airfreight (including International Express Mailing Service).

 

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN REDACTED PROVISIONS OF THIS AGREEMENT AND, WHERE APPLICABLE, HAVE BEEN MARKED WITH AN ASTERISK (****) TO DENOTE WHERE OMISSIONS HAVE BEEN MADE.  THE CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

Except as the parties may otherwise agree in writing, all sales of the Products by Supplier to Iradimed hereunder shall be made on the basis of F.O.B. any Japanese -or airport (including post office).

 

ARTICLE 8                                                                           TITLE AND RISK

 

The title to and risk of the Products shall pass to Iradimed at the time when delivered by Supplier at F.O.B. point.

 

ARTICLE 9                                                                           WARRANTY

 

9.1                               Supplier warrants that the Products meet the Specification required by Iradimed and the designs by the Supplier and are free from defects in material and workmanship. This warranty by the Supplier shall continue for a period of twelve (12) months from at the date of the shipment stipulated in the Article 9.3.

 

9.2                               Supplier shall not be responsible for such defect in the event that such defect arises from:

 

(i)                                     wilful damage to or misuse of the Products by Iradimed, its employees or customers; or

 

(ii)                                  proven negligence or misconduct on the part of Iradimed, its employees or customers;

 

(iii)                               failure by Iradimed, its employees or customers to comply with the written instructions contained in the Supplier’s Manual or similar.

 

9.3                               Without prejudice to the Iradimed’s other rights under this Agreement or at law, if Iradimed discovers any breach of the warranty stipulated in Article 9.1 on the Products delivered within twelve (12) months from the issuing date of the air waybill, it may at its sole discretion;

 

(i)                                     notify Supplier that it requires Supplier to replace the Products or replace any part thereof; or

 

(ii)                                  replace the Products or repair any part thereof itself or arrange for such repair to be undertaken by a third party in which case necessary reimbursement is made with respect to such repairs being undertaken by a third party.

 

9.4                               The warranty set forth herein is in lieu of any and all other warranties express or implied including the warranties or merchantability and/or fitness for special purpose.

 

Supplier shall not be liable for any indirect and/or consequential damages.

 

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN REDACTED PROVISIONS OF THIS AGREEMENT AND, WHERE APPLICABLE, HAVE BEEN MARKED WITH AN ASTERISK (****) TO DENOTE WHERE OMISSIONS HAVE BEEN MADE.  THE CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

ARTICLE 10                                                                    LIMITATION OF LIABILITY

 

In no event shall Supplier be liable to Iradimed, whether in contract or in tort or under any other legal theory, for lost profits or revenues, loss of use or similar economic loss, or for any indirect, special, incidental, consequential or similar damages arising out of or in connection with the sale, storage, use, maintenance, condition or possession of the Products, or for any claim made against Iradimed by any other party, even if Supplier has been advised of the possibility of such claim.

 

In no event shall Supplier’s liability under any claim made by Iradimed exceed the purchase price actually paid by Iradimed for the Products in respect of which such claim is made.

 

ARTICLE 11                                                                    CONFIDENTIALITY

 

Except as required by law, regulation, legal process, or similar process, each party:

 

(i)                                     shall keep all Confidential Information confidential and shall not disclose and Confidential Information to any third party; and

 

(ii)                                  shall not use any Confidential Information for any purpose other than the evolution of the proposed transaction or the consummation of the proposed transaction.

 

ARTICLE 12                                                                    FORCE MAJEURE

 

Neither party shall be held responsible for failure or delay to perform all or any part of this Agreement if the performance of any part of this Agreement shall be interfered with for any length of time by riots, war, acts of God, fire, storm, flood, earthquake, strikes or any other similar or dissimilar causes which are beyond the control of the parties hereto. If such delay or failure shall continue for a period of more than three (3) months, either party hereto may terminate this Agreement with a written notice to the party, without any liability being attached to any of the party hereto.

 

ARTICLE 13                                                                    TERMINATION

 

Either party may terminate this Agreement immediately upon written notice if:

 

(i)                                     the other party fails to perform any obligation under this Agreement including but not limited to failure or default in payment any money when due hereunder, and such failure not being cured within (21) days after the date or notice hereof requiring the other party to remedy such failure;

 

(ii)                                  default in yearly minimum purchase obligation of article 3;

 

(iii)                               the other party makes or offers to make a corporate arrangement or composition with or for the benefit of its creditors;

 

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN REDACTED PROVISIONS OF THIS AGREEMENT AND, WHERE APPLICABLE, HAVE BEEN MARKED WITH AN ASTERISK (****) TO DENOTE WHERE OMISSIONS HAVE BEEN MADE.  THE CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

(iv)                              a petition or resolution for the making of the winding up, or the dissolution of the other party is presented or passed; or

 

(v)                                 a liquidator, receiver, administrator takes possession of or is appointed over the Whole or any part of the assets of the other party;

 

(vi)                              Neither party may terminate this Agreement other than pursuant to this Agreement.

 

Expiry or valid termination hereof shall not affect any accrued rights or liabilities of either party or claims which either party may have against the other for prior breach.

 

ARTICLE 14                                                                    OBLIGATION AFTER TERMINATION

 

14.1                        The provisions of the Agreement shall, in the event of expiration or termination thereof, continue to apply to rights and duties of the parties existing under this Agreement or sales contract thereunder, at the time of termination or expiration of this Agreement, provided, however, that Supplier shall have an option to cancel without any liability an order accepted but not performed before such termination or expiration.

 

14.2                        Iradimed shall not be entitled to indemnities, damages or other compensation of any kind as a result of expiration or termination of this Agreement, except for fault of Supplier.

 

ARTICLE 15                                                                    GOVERNING LAW

 

15.1                        This Agreement and any dispute or claim arising out of or in connection with it shall be governed by and construed in all respects in accordance with the laws of Japan.

 

15.2                        The courts of Japan are to have non-exclusive jurisdiction to settle any dispute which may arise out of or in connection with this Agreement and the documents to be entererd into pursuant to it. Iradimed and Supplier irrevocably submit to the jurisdiction of such courts. This ARTICLE 14.2 shall not limit its right to bring Proceeding in any other court of competent jurisdiction in any country.

 

ARTICLE 16                                                                    GENERAL PROVISIONS

 

16.1                        This Agreement may only be amended by a written instrument duly executed by Iradimed and Supplier.

 

16.2                        This Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns.

 

16.3                        This Agreement embodies the entire agreement and understanding of the Parties and merges all prior discussions and negotiations between them.

 

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN REDACTED PROVISIONS OF THIS AGREEMENT AND, WHERE APPLICABLE, HAVE BEEN MARKED WITH AN ASTERISK (****) TO DENOTE WHERE OMISSIONS HAVE BEEN MADE.  THE CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

16.4                        Notices will be addressed as follows:

 

	
If to Iradimed:
    	
Iradimed Corp
    
	
 
    	
 
    
	
 
    	
7457 Aloma Ave.
    
	
 
    	
 
    
	
 
    	
Winter Park, FL 32792 USA
    
	
 
    	
 
    
	
 
    	
Roger Susi
    
	
 
    	
 
    
	
 
    	
Fax no: #001 407 677-5037
    
	
 
    	
 
    
	
If to Supplier:
    	
****
    
	
 
    	
 
    
	
 
    	
****
    
	
 
    	
 
    
	
 
    	
****
    
	
 
    	
 
    
	
 
    	
****
    
	
 
    	
 
    
	
 
    	
JAPAN
    
	
 
    	
 
    
	
 
    	
Attn: ****
    
	
 
    	
 
    
	
 
    	
Fax no: ****
    

 

16.5                        If there is any conflict between any provisions of this Agreement with any provision of an Exhibit or purchase order, the provisions of this Agreement shall prevail.

 

16.6                        Each party represents and warrants to others, that it has full power and authority to enter into this Agreement and any agreements related hereto and, subject terms and conditions hereof, this Agreement, when executed will be a valid and legally binding obligation of such party according to its provisions;

 

16.7                        Notwithstanding the preparation or existence of any other language, the Japanese version prevail.

 

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN REDACTED PROVISIONS OF THIS AGREEMENT AND, WHERE APPLICABLE, HAVE BEEN MARKED WITH AN ASTERISK (****) TO DENOTE WHERE OMISSIONS HAVE BEEN MADE.  THE CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed in a manner legally binding upon them.

 

	
Iradimed Corp
    	
 
    	
****
    
	
 
    	
 
    	
 
    
	
Winter Park, FL 32792 USA
    	
 
    	
****, Japan
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Signature:
    	
/s/ Roger Susi
    	
 
    	
Signature: ****
    
	
 
    	
 
    	
 
    
	
Name: Roger Susi
    	
 
    	
Name: ****
    
	
 
    	
 
    	
 
    
	
Title: President
    	
 
    	
Title: ****
    
	
 
    	
 
    	
 
    
	
Date:
    	
 
    	
Date: 3 March, 2014

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]